Glaxo to launch five vaccines over five years

Share this article:
GlaxoSmithKline said it expects to launch five major vaccines in the next five years with the potential to reach total annual sales between $10 billion and $18 billion.
Among the vaccines is Cervarix, a cervical-cancer vaccine, considered to be the most promising product of the group.
Filing for Cervarix approval in Europe is expected in early 2006 with a U.S. filing expected later next year. Glaxo said Cervarix could achieve sales between $3.5 billion and $7 billion.
Other vaccines being readied for launch by 2010 include Rotarix for gastroenteritis, Streptorix for pneumococcal infections, a combination vaccine for meningitis and an improved vaccine for influenza.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.